STOCK TITAN
  1. Home
  2. News
  3. RGNX

REGENXBIO To Present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ROCKVILLE, Md., April 21, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that Curran M. Simpson, Chief Operations and Technology Officer, will present at the Chardan 5th Annual Genetic Medicines Manufacturing Summit on Tuesday, April 27, 2021 at 3:15 p.m. ET. The conference will be held in a virtual meeting format.

A webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the fireside chat.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com  

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-present-at-the-chardan-5th-annual-genetic-medicines-manufacturing-summit-301273377.html

SOURCE REGENXBIO Inc.

Stock RGNX logo
REGENXBIO Inc.

NASDAQ:RGNX

RGNX Rankings

#2586 Ranked by Market Cap
#4288 Ranked by Stock Gains
N/A Ranked by Dividends

RGNX Latest News

May 1, 2024
REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
Apr 24, 2024
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 28, 2024
REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
Mar 27, 2024
REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
Mar 11, 2024
REGENXBIO to Participate in Upcoming Investor Conferences

RGNX Stock Data

825.39M
37.36M
7.18%
81.62%
8.05%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
ROCKVILLE

About RGNX

regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.